A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients

Trial Profile

A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top